Cascade Financial Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$273M Sell
235,707
-1,000
-0.4% -$1.18M 22.85% 1
2026
Q2
$284M Buy
236,707
+25
+0% +$25.5K 24.65% 1
2026
Q1
$218M Buy
236,682
+65
+0% +$65.9K 22.44% 1
2025
Q4
$254M Sell
236,617
-90
-0% -$86.1K 25.78% 1
2025
Q3
$181M Buy
236,707
+651
+0.3% +$484K 20.71% 1
2025
Q2
$184M Buy
236,056
+1,070
+0.5% +$831K 22.12% 1
2025
Q1
$194M Buy
234,986
+21
+0% +$17.5K 24.47% 1
2024
Q4
$181M Buy
234,965
+137
+0.1% +$113K 23.64% 1
2024
Q3
$213M Buy
234,828
+728
+0.3% +$655K 26.76% 1
2024
Q2
$212M Buy
234,100
+67
+0% +$53.6K 27.86% 1
2024
Q1
$176M Buy
+234,033
New +$167M 25.34% 1

Other funds holding LLY

Cascade Financial Partners's LLY Position: Q3 2026 in Review

Cascade Financial Partners reduced its Eli Lilly (LLY) stake by 0.42% in Q3 2026, selling an estimated $1.18M and leaving 235,707 shares worth $273M. The position accounts for 22.85% of the portfolio, ranked #1.

Cascade Financial Partners first reported a position in LLY in Q1 2024 and has held it in 11 quarters since. The position peaked at $284M in Q2 2026. 4,628 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Cascade Financial Partners held 235,707 shares of Eli Lilly worth $273M as of Q3 2026.
  • Cascade Financial Partners sold 1,000 Eli Lilly shares in Q3 2026, an estimated $1.18M.
  • Eli Lilly made up 22.85% of Cascade Financial Partners's portfolio in Q3 2026, its #1 holding.
  • Cascade Financial Partners first reported a position in Eli Lilly in Q1 2024 and has held it in 11 quarters since.
  • Cascade Financial Partners's Eli Lilly position peaked at $284M in Q2 2026.
  • 4,628 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Cascade Financial Partners's 13F filing for Q3 2026, filed 16 Nov 2026.